Precision Biopsy appoints Adam Savakus as Chief Operating Officer

Allied Minds subsidiary, Precision Biopsy, has announced the appointment of Adam Savakus as Chief Operating Officer.

This appointment represents an important investment in Precision Biopsy’s regulatory and clinical expertise at a key juncture in its development as its lead diagnostic product, ClariCore, enters a pivotal Cohort B study.

Savakus said: “I am excited to be joining the Precision Biopsy team given the promising clinical trial results to date and I look forward to bringing my experience and contacts to bear as ClariCore enters its pivotal Cohort B study.”

Savakus is an accomplished medical device executive with direct experience driving successful operational, regulatory and marketing outcomes. Most recently as Executive VP at Relievant MedSystems, he was responsible for clinical and regulatory strategy design and execution for the Intracept device targeted at relief of chronic lower back pain.

As with Precision Biopsy’s ClariCore product, Intracept under Savakus’s leadership secured a 510(k) approval pathway and was ultimately approved by the FDA in July 2016.

Prior to Relievant, Savakus served as VP, Cinical and Regulatory Affairs at Adiana (later Cytyc), and as VP, Clinical and Regulatory Affairs and Quality Assurance at EndoSonics. Savakus holds a BSc in Biophysics and a BSc Bioengineering, both from The Pennsylvania State University.

Jill Smith, CEO of Allied Minds, commented: “We are delighted to make this investment in additional talent at Precision Biopsy. We believe Adam’s direct experience in leading successful FDA outcomes, as well as in marketing and quality control, will be invaluable to the Precision Biopsy team.”

You may also like

Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success

Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Regulatory

Isospec Analytics launches biomolecular analysis technology to identify unknown molecules

The novel technology optimises the identification process of unknown molecules compared to mass analysis
Regulatory

4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA

The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
Regulatory

The key role of IVDs in healthcare: challenges to commercialisation and access

In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
Subscribe now